Kerry Blanchard has resigned as CEO of Everest Medicines with immediate effect. While the Chinese drug developer only shared the news on Thursday evening, it has spent the past few months searching for a CEO, putting it on course to appoint a successor to Blanchard in the coming month.

The Association of Clinical Research Organizations (ACRO) is stepping up its efforts to address the age-old problem of the lack of diversity in clinical trial populations. With its principles statement, the trade group has set out what its members will do to make clinical trials—and their own workforces—more diverse.

Sometimes, finding out that an enzyme doesn’t work the way you thought it did means you have to go back to the drawing board. Then there are times when it turns out to be a fortuitous discovery that could pave the way for treatments for one of medicine’s most challenging conditions— in this case, sepsis.

It's shaping up to be the patent fight of the pandemic era as Moderna files lawsuits in the United States and Germany accusing Pfizer and BioNTech of infringing its patents that date back to 2010.

Just a few months after Fitbit roped in FDA clearance for an algorithm that could be embedded into its eponymous health-tracking wearables to detect atrial fibrillation, the technology is ready to hit the ground running.

An anticipated merger between Merck and Seagen has stalled because the companies can’t agree on a price, Bloomberg reports. The potential deal—which was rumored to be valued at around $40 billion—remains on the table and could still happen soon, the new outlet reports.

With a device that’s now been cleared in both the U.S. and Europe, preparing a patient for an EEG test is almost as easy as strapping on a bike helmet.

Former Takeda exec Willemsen takes reins at Tessa. Former bluebird regulatory chief jumps aboard gene editing-focused Flagship company Tessera. Aeglea CEO departs after the company is stymied by FDA.

This week on "The Top Line," we discuss Genentech’s Greg Rippon's remarks on missing the mark in terms of diverse trial recruitment and how the company hopes to get it right in the future. We'll also chat about a new report on brand awareness for diabetes drugs.

Takeda's dengue shot has won its first approval anywhere. Eisai has debuted its new U.S. headquarters . In relief for several New York-listed Chinese biotechs, U.S. and Chinese authorities have reached a deal that would allow American accounting watchdogs access to Chinese companies’ audit records. And more.

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella.

Set a solid foundation for successful scale-up of buffer preparation.

The total immersion, transformative training will take place at the Harvard Club in Boston. VIRTUAL in real time is also available. Contingencies for COVID19 will apply. Register NOW for a large early bird discount www.drugstomarket.com/drugbootcamp.

The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services.

See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead.

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.